McBride (LSE: MCB) to acquire Eurotab Group to cement Unit Dosing leadership in Europe

McBride plc (LSE: MCB), the Manchester-based private label household cleaning and hygiene manufacturer, announced on 2 April 2026 that its Unit Dosing division has submitted a binding offer to acquire the Eurotab Group from shareholders of Eurotop SAS for an expected cash consideration of EUR 40 million (approximately GBP 34.5 million), subject to customary closing adjustments. Eurotab, a privately held specialist in solid-format detergent manufacturing headquartered in France, operates two production facilities in France and a third in Turkey, and is expected to report consolidated revenues of EUR 65 million for the year to 30 June 2026. The deal, financed entirely through McBride’s existing banking facilities, is designed to accelerate the group’s progress toward a 10 percent EBITDA margin target set at its 2024 Capital Markets Day. McBride’s shares were trading at approximately 139 pence on the London Stock Exchange on announcement day, within a 52-week range of 106.20p to 170.00p, implying a market capitalisation of around GBP 239 million.

What does the Eurotab acquisition mean for McBride’s Unit Dosing division and its 10 percent EBITDA margin target?

McBride’s Unit Dosing division, which manufactures dishwasher tablets, laundry capsules, and water softeners, has been the group’s most strategically significant growth engine over the past several years. Eurotab’s product suite, which includes automatic dishwasher tabs, moisture-absorbing solutions, and disinfecting bleach tablets, augments the division with two product categories it did not previously serve at scale. That directly addresses a recurring tension in the unit dosing segment: strong commercial momentum constrained by finite production capacity. The addition of Eurotab’s free production capacity resolves at least part of that constraint while avoiding the capital expenditure timeline associated with building out McBride’s own facilities.

McBride management has framed the acquisition as adding approximately 0.5 percentage points to the group’s EBITDA margin, a meaningful increment for a business operating at a mid-single-digit margin today. The group finished its first half of FY2026 with an adjusted EBIT margin of 6.6 percent, placing the 10 percent target in the outer years of the current strategic plan. Eurotab’s contribution, combined with the synergies the group expects to realise over time, nudges that trajectory forward, though it does not close the gap in isolation.

How does the EUR 40 million price and 5.2x EBITDA multiple stack up against comparable European private label deals?

The enterprise value for the transaction is currently expected at EUR 38.2 million, with an additional EUR 1.8 million representing the attributed value of acquired tax losses, bringing the headline figure to EUR 40 million. Against Eurotab’s closing 12-month EBITDA, that implies a purchase multiple of 5.2 times on an underlying basis, or 4.6 times once the tax losses are netted out. McBride further asserts that adjusting for conservative synergies reduces the effective multiple to 3.1 times. For context, private label consumer goods transactions in Europe have typically cleared at multiples ranging from 6 to 9 times EBITDA over the past several years, depending on growth profile and asset quality. A 5.2 times headline entry for a business with EUR 65 million in revenues, operating two specialised manufacturing facilities with proprietary powder compaction technology, sits at the lower end of that range. That relative discount likely reflects the maturity of Eurotab’s existing customer relationships, its private ownership structure, and the French legal requirements that govern the transaction timeline. It also reflects the fact that free production capacity, while attractive strategically, implies Eurotab has not yet maximised the throughput those assets could generate. The acquirer assumes that execution risk.

Why does the French employee consultation requirement introduce timing risk and what happens if it delays closing?

The completion of this acquisition is not simply a matter of agreeing commercial terms. Under applicable French law, the binding offer made by McBride is conditional on the completion of information and consultation procedures with French employees and their representative bodies at the Eurotab Group. This is a procedural requirement embedded in French labour law that applies to material corporate transactions affecting French workforces. The timeline for these consultations is not entirely within McBride’s control. McBride has guided that the transaction is expected to close between June 2026 and the end of the first quarter of the group’s FY2027 financial year, implying a window stretching through to approximately September 2026. A deal that closes in September rather than June delays earnings accretion by roughly one quarter, which is commercially meaningful but not transformative. The more substantive risk is that consultation processes in France occasionally surface employee or union opposition that complicates or, in rarer cases, derails transactions. McBride has not indicated any specific concerns on this front, and Eurotab appears to be a relatively focused manufacturing business rather than a complex restructuring candidate, which reduces but does not eliminate procedural friction.

How does McBride plan to finance the Eurotab deal and what does net debt headroom look like post-acquisition?

McBride has confirmed that the EUR 40 million consideration will be drawn from existing banking facilities, requiring no new equity issuance and causing no disruption to the current share buyback programme. The group’s Capital Markets Day target was to operate at a net debt to EBITDA ratio of no more than 1.5 times. McBride has flagged that the acquisition will push that ratio slightly above this threshold for approximately one year post-completion, after which it expects to return within range through organic cash generation. That is a credible trajectory provided the underlying business continues to perform at current levels, but it leaves the group with limited balance sheet flexibility in the near term. Any material deterioration in trading, or any unexpected integration cost, could push the leverage recovery timeline out further. McBride’s half-year results to December 2025 showed the business on track against full-year targets, and management confirmed at the time that new contract wins underpinned a positive outlook for the second half of FY2026. Against that backdrop, the incremental borrowing appears manageable, though the input cost pressures disclosed alongside the acquisition announcement introduce a degree of uncertainty into that assessment.

What is the strategic logic behind Eurotab’s Turkish manufacturing facility and what new markets could it unlock for McBride?

McBride’s announcement identifies Eurotab’s Turkish manufacturing facility, located near Istanbul, as a platform for expanding group manufacturing capabilities and accessing new target markets over time. That framing is deliberately vague, but the geography is instructive. Turkey straddles European and Middle Eastern consumer markets, sits at a logistics crossroads connecting Central Asia, the Levant, and North Africa, and has a large and growing domestic cleaning products sector. For a group currently concentrated in Western and Central Europe, a Turkish manufacturing base provides optionality in markets where private label penetration remains lower than in mature European markets, and where demand growth rates are structurally higher. Eurotab’s Turkish operation is described as smaller than its French facilities, implying it is a commercial rather than core manufacturing asset at this point. The real question is whether McBride intends to invest in expanding Turkish capacity as a genuine export platform, or whether the Turkey reference is primarily a framing device for a deal whose strategic rationale is otherwise European in scope. Either interpretation is plausible, but the latter carries less execution complexity and is therefore more likely in the near term.

How do rising petrochemical input costs and Middle East conflict-related surcharges affect McBride’s near-term margin outlook?

Alongside the Eurotab announcement, McBride disclosed a notable deterioration in its input cost environment. The group has flagged that chemical and packaging suppliers, facing higher petrochemical feedstock costs and elevated energy expenses linked to ongoing conflict in the Middle East, have begun implementing price increases. McBride stated that the first signs of possible supply chain shortages are also beginning to emerge. In response, the group has already notified all customers of temporary price adjustments and surcharges to recover what it characterises as beyond-its-control cost increases. This is a significant development in isolation, but it arrives at a delicate moment for the acquisition narrative. McBride is acquiring a EUR 65 million revenue business while its own cost base is under pressure, and while the group’s leverage is about to increase above its stated target. The saving grace, historically, is that private label cleaning products tend to benefit from trade-down behaviour during periods of consumer cost pressure, with shoppers substituting branded products for private label equivalents. McBride management cited this dynamic explicitly, noting resilient and growing private label demand during previous periods of global macro uncertainty. The pattern is real and well-documented, but it operates over months rather than quarters, and offers little protection against the near-term margin compression that input cost inflation will deliver before customer surcharges fully take effect.

How does the McBride share price trajectory and analyst consensus compare with the strategic signals from this acquisition?

McBride shares were trading at approximately 139 pence on the day of this announcement, against a 52-week range of 106.20p to 170.00p and an analyst consensus price target of around 183p to 198p. That implies meaningful upside from current levels in the view of covering analysts, all of whom currently carry buy recommendations on the stock. The group’s own board has made its assessment clear: the share buyback programme continues, and the acquisition announcement was accompanied by a CEO statement characterising the market capitalisation as significantly undervalued. That dual signal, capital deployed externally on value-accretive M&A while returning capital to shareholders simultaneously, is the kind of capital allocation discipline that institutional investors typically reward over time. The acquisition at 5.2 times EBITDA compares favourably with McBride’s own valuation of approximately 8 times earnings, suggesting the group is buying growth at a lower multiple than the market currently assigns to its own earnings stream. That arithmetic is compelling, provided integration delivers against the synergy case and the input cost headwinds prove transitory rather than structural.

Key takeaways: What the McBride Eurotab deal means for investors, competitors, and the European private label detergent market

• McBride plc has made a binding offer to acquire Eurotab Group for EUR 40 million, funded through existing facilities with no equity dilution and no disruption to the share buyback programme.
• The headline EBITDA acquisition multiple of 5.2 times, or 3.1 times adjusted for synergies, represents a financially disciplined entry into a complementary manufacturing asset.
• Eurotab’s free production capacity directly addresses capacity constraints in McBride’s Unit Dosing division, supporting revenue growth at a lower incremental capital expenditure cost than organic capacity expansion.
• Two new product categories, moisture-absorbing solutions and disinfecting bleach tablets, broaden McBride’s addressable market and reduce divisional concentration risk.
• The acquisition is expected to add approximately 0.5 percentage points to Group EBITDA margin and represents a measurable step toward the 10 percent target set at the 2024 Capital Markets Day.
• Net debt to EBITDA is expected to exceed the 1.5 times Capital Markets Day target for approximately one year post-completion, limiting near-term balance sheet flexibility.
• French employee consultation requirements introduce a closing window of June 2026 to September 2026, creating a potential one-quarter variance in earnings accretion timing.
• McBride’s Turkish manufacturing exposure through Eurotab opens optionality in faster-growing adjacent markets, though the facility is currently small in scale.
• Rising petrochemical input costs linked to Middle East conflict are a near-term margin headwind, partially offset by customer surcharges already in motion and the structural tailwind of trade-down demand for private label products.
• Analyst consensus carries a strong buy rating with a target price of around 183p to 198p against a current trading price near 139p, suggesting the market has not fully priced the strategic progress underway at McBride.